Ayman Yosry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ayman Yosry has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Marwan
Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
1 shared publication - Ehab E. Abdel-Khalek
Department of Internal Medicine, Division of Gastroenterology, Liver Transplant Unit, Mansoura University, Mansoura, Egypt
1 shared publication - Gamal Esmat
Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
1 shared publication - Hadeel Gamal Eldeen
Liver Transplantation Unit, Cairo University, Cairo, Egypt
1 shared publication - Hoda Ahmed Makhlouf
Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt
1 shared publication - Imam Waked
Steatotic Liver Diseases Study Foundation in Middle East and North Africa (SLMENA), Cairo, Egypt.; Hepatology Department, National Liver Institute, Menoufia University, Shebeen ElKom, Egypt
1 shared publication
Latest Publications
- Open Access
- 11 May 2026
- Published by Springer Nature in Egyptian Liver Journal
- Vol. 16 (1) , 30
Conference recommendations on immunosuppression practice for adult liver transplantation in Egypt
Background: Adult living donor liver transplantation (LDLT) started in Egypt in 2001, with more than 5000 cases transplanted since then. In Egypt using only ABO compatible donor is the practice in all cases, and up till now, the only oncological indication for LDLT is hepatocellular carcinoma (HCC). The optimal management of the transplant recipient relies on understanding and proper utilization of immunosuppression regimens. The clinician should be aware of how to maintain the delicate balance between under-immunosuppression, leading to graft rejection, and over-immunosuppression, leading to the consequences of immunodeficiency such as sepsis and malignancy. The aim of this consensus is to provide clinical guidance to transplant physicians, transplant surgeons, clinical pharmacologists and nurses about immunosuppression in LDLT recipients. Main body: These national recommendations on immunosuppression in adult LDLT were developed by an experience exchange between the 22 centers currently undergoing LDLT in Egypt. A group of experts in liver transplantation from all over Egypt participated in the review of literature for different aspects related to these recommendations and, then they shared in formulation of several statements. In the United Conference on Hepato-gastroenterology and Infectious Diseases (UCHID) (2022), voting on these statements was done. Conclusion: Comprehensive national guidance is provided regarding the general principles of liver transplant immunosuppression, types of immunosuppression (IS), established IS drugs, types of rejection and their management, treatment of special groups, immunosuppression minimization, immune tolerance and complete IS withdrawal and the role of liver biopsy in orchestrating immunosuppression.
- 11 May 2026
- Published by Springer Nature in Egyptian Liver Journal
- Vol. 16 (1) , 30
Open AccessConference recommendations on immunosuppression practice for adult liver transplantation in Egypt
Background: Adult living donor liver transplantation (LDLT) started in Egypt in 2001, with more than 5000 cases transplanted since then. In Egypt using only ABO compatible donor is the practice in all cases, and up till now, the only oncological indication for LDLT is hepatocellular carcinoma (HCC). The optimal management of the transplant recipient relies on understanding and proper utilization of immunosuppression regimens. The clinician should be aware of how to maintain the delicate balance between under-immunosuppression, leading to graft rejection, and over-immunosuppression, leading to the consequences of immunodeficiency such as sepsis and malignancy. The aim of this consensus is to provide clinical guidance to transplant physicians, transplant surgeons, clinical pharmacologists and nurses about immunosuppression in LDLT recipients. Main body: These national recommendations on immunosuppression in adult LDLT were developed by an experience exchange between the 22 centers currently undergoing LDLT in Egypt. A group of experts in liver transplantation from all over Egypt participated in the review of literature for different aspects related to these recommendations and, then they shared in formulation of several statements. In the United Conference on Hepato-gastroenterology and Infectious Diseases (UCHID) (2022), voting on these statements was done. Conclusion: Comprehensive national guidance is provided regarding the general principles of liver transplant immunosuppression, types of immunosuppression (IS), established IS drugs, types of rejection and their management, treatment of special groups, immunosuppression minimization, immune tolerance and complete IS withdrawal and the role of liver biopsy in orchestrating immunosuppression.